Abstract |
In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. The anidulafungin MIC distribution showed that Candida albicans and C. glabrata were the most susceptible species and C. parapsilosis was the least susceptible species.
|
Authors | M A Pfaller, D J Diekema, L Boyken, S A Messer, S Tendolkar, R J Hollis, B P Goldstein |
Journal | Antimicrobial agents and chemotherapy
(Antimicrob Agents Chemother)
Vol. 49
Issue 11
Pg. 4795-7
(Nov 2005)
ISSN: 0066-4804 [Print] United States |
PMID | 16251335
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antifungal Agents
- Echinocandins
- Peptides, Cyclic
- Anidulafungin
|
Topics |
- Adult
- Anidulafungin
- Antifungal Agents
(therapeutic use)
- Candida
(drug effects)
- Candidiasis
(drug therapy)
- Echinocandins
- Humans
- Microbial Sensitivity Tests
- Peptides, Cyclic
(therapeutic use)
|